Hypotension after induction of anesthesia with remimazolam or etomidate: a non-inferiority randomized controlled trial in patients undergoing coronary artery bypass grafting
Korean Journal of Anesthesiology · 01.04.2025 · 78 (2) · 139-147
DOI: 10.4097/kja.24537 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Korean Journal of Anesthesiology, erschienen am 01.04.2025. Verfasst von Jeong-Jin Min und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Etomidate, Coronary Artery Bypass, Hypotension, Anesthetics, Intravenous. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hana Pharm Co., Ltd.
Abstract (Originalsprache)
Background
Remimazolam is a novel ultra-short-acting benzodiazepine known for its hemodynamic stability over propofol. However, its hemodynamic effects compared to those of etomidate are not well established. This study aimed to determine whether the use of remimazolam is non-inferior to etomidate with regard to the occurrence of post-induction hypotension in patients undergoing coronary artery bypass grafting.
Methods
Patients were randomly assigned to either the remimazolam group (6 mg/kg/h) or the etomidate group (0.3 mg/kg) for induction of anesthesia. Anesthetic depth was adjusted based on the bispectral index. Primary outcome was the incidence of post-induction hypotension, defined as a mean arterial pressure less than 65 mmHg within 15 min after endotracheal intubation, with a non-inferiority margin of 12%.
Results
A total of 144 patients were finally analyzed. Incidence of post-induction hypotension was 36/71 (50.7%) in the remimazolam group and 25/73 (34.2%) in the etomidate group, with a rate difference of 16.5% (95% CI [3.0–32.6]) between the two groups that was beyond the prespecified non-inferiority margin of 12.0%. The number of patients who needed vasopressors was similar in the two groups.
Conclusions
In this non-inferiority trial, remimazolam failed to show non-inferiority to etomidate in terms of post-induction hypotension when used as an induction drug for general anesthesia in patients undergoing coronary artery bypass grafting. However, different doses or infusion techniques of remimazolam should be compared with etomidate in various patient groups to fully assess its hemodynamic non-inferiority during induction of anesthesia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Anesthesiology and Pain Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Förderung
- Hana Pharm Co., Ltd
Zitieren
APA
Min, J. J., Oh, E. J., Hwang, H. J., Jo, S., Cho, H., Kim, C., & Lee, J. H. (2025). Hypotension after induction of anesthesia with remimazolam or etomidate: a non-inferiority randomized controlled trial in patients undergoing coronary artery bypass grafting. Korean Journal of Anesthesiology, 78(2), 139-147. https://doi.org/10.4097/kja.24537
Vancouver
Min JJ, Oh EJ, Hwang HJ, Jo S, Cho H, Kim C, et al. Hypotension after induction of anesthesia with remimazolam or etomidate: a non-inferiority randomized controlled trial in patients undergoing coronary artery bypass grafting. Korean Journal of Anesthesiology. 2025;78(2):139-147. doi:10.4097/kja.24537
BibTeX
@article{Min2025,
author = {Min, Jeong-Jin and Oh, Eun Jung and Hwang, Hyun Ji and Jo, Sungwoo and Cho, Hyunsung and Kim, Chungsu and Lee, Jong-Hwan},
title = {Hypotension after induction of anesthesia with remimazolam or etomidate: a non-inferiority randomized controlled trial in patients undergoing coronary artery bypass grafting},
journal = {Korean Journal of Anesthesiology},
year = {2025},
volume = {78},
number = {2},
pages = {139--147},
doi = {10.4097/kja.24537}
}
EUVIMED